130 related articles for article (PubMed ID: 36229686)
1. Targeting lipid-protein interaction to treat Syk-mediated acute myeloid leukemia.
Singaram I; Sharma A; Pant S; Lihan M; Park MJ; Pergande M; Buwaneka P; Hu Y; Mahmud N; Kim YM; Cologna S; Gevorgyan V; Khan I; Tajkhorshid E; Cho W
Nat Chem Biol; 2023 Feb; 19(2):239-250. PubMed ID: 36229686
[TBL] [Abstract][Full Text] [Related]
2. Role of electrostatic interactions in SH2 domain recognition: salt-dependence of tyrosyl-phosphorylated peptide binding to the tandem SH2 domain of the Syk kinase and the single SH2 domain of the Src kinase.
Grucza RA; Bradshaw JM; Mitaxov V; Waksman G
Biochemistry; 2000 Aug; 39(33):10072-81. PubMed ID: 10955995
[TBL] [Abstract][Full Text] [Related]
3. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
4. Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.
Visperas PR; Winger JA; Horton TM; Shah NH; Aum DJ; Tao A; Barros T; Yan Q; Wilson CG; Arkin MR; Weiss A; Kuriyan J
Biochem J; 2015 Jan; 465(1):149-61. PubMed ID: 25287889
[TBL] [Abstract][Full Text] [Related]
5. Src homology 2 domains of Syk and Lyn bind to tyrosine-phosphorylated subunits of the high affinity IgE receptor.
Kihara H; Siraganian RP
J Biol Chem; 1994 Sep; 269(35):22427-32. PubMed ID: 8071371
[TBL] [Abstract][Full Text] [Related]
6. Distinctive functions of Syk N-terminal and C-terminal SH2 domains in the signaling cascade elicited by oxidative stress in B cells.
Ding J; Takano T; Hermann P; Gao S; Han W; Noda C; Yanagi S; Yamamura H
J Biochem; 2000 May; 127(5):791-6. PubMed ID: 10788787
[TBL] [Abstract][Full Text] [Related]
7. SYK regulates mTOR signaling in AML.
Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.
Narula SS; Yuan RW; Adams SE; Green OM; Green J; Philips TB; Zydowsky LD; Botfield MC; Hatada M; Laird ER
Structure; 1995 Oct; 3(10):1061-73. PubMed ID: 8590001
[TBL] [Abstract][Full Text] [Related]
9. SH2 domain-mediated targeting, but not localization, of Syk in the plasma membrane is critical for FcepsilonRI signaling.
Sada K; Zhang J; Siraganian RP
Blood; 2001 Mar; 97(5):1352-9. PubMed ID: 11222380
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains.
Woodside DG; Obergfell A; Talapatra A; Calderwood DA; Shattil SJ; Ginsberg MH
J Biol Chem; 2002 Oct; 277(42):39401-8. PubMed ID: 12171941
[TBL] [Abstract][Full Text] [Related]
12. SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Puissant A; Fenouille N; Alexe G; Pikman Y; Bassil CF; Mehta S; Du J; Kazi JU; Luciano F; Rönnstrand L; Kung AL; Aster JC; Galinsky I; Stone RM; DeAngelo DJ; Hemann MT; Stegmaier K
Cancer Cell; 2014 Feb; 25(2):226-42. PubMed ID: 24525236
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase.
Moon KD; Post CB; Durden DL; Zhou Q; De P; Harrison ML; Geahlen RL
J Biol Chem; 2005 Jan; 280(2):1543-51. PubMed ID: 15536084
[TBL] [Abstract][Full Text] [Related]
14. Identification of the site in the Syk protein tyrosine kinase that binds the SH2 domain of Lck.
Couture C; Deckert M; Williams S; Russo FO; Altman A; Mustelin T
J Biol Chem; 1996 Sep; 271(39):24294-9. PubMed ID: 8798676
[TBL] [Abstract][Full Text] [Related]
15. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.
Gioia R; Leroy C; Drullion C; Lagarde V; Etienne G; Dulucq S; Lippert E; Roche S; Mahon FX; Pasquet JM
Blood; 2011 Aug; 118(8):2211-21. PubMed ID: 21730355
[TBL] [Abstract][Full Text] [Related]
16. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
17. Activation of the high-affinity immunoglobulin E receptor Fc epsilon RI in RBL-2H3 cells is inhibited by Syk SH2 domains.
Taylor JA; Karas JL; Ram MK; Green OM; Seidel-Dugan C
Mol Cell Biol; 1995 Aug; 15(8):4149-57. PubMed ID: 7623809
[TBL] [Abstract][Full Text] [Related]
18. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.
Lottin-Divoux S; Jean D; Le Romancer M; Frade R
Cell Signal; 2006 Aug; 18(8):1219-25. PubMed ID: 16289966
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A; Ellegast JM; Alexe G; Frank ES; Ross L; Chu SH; Pikman Y; Robichaud A; Goodale A; Häupl B; Mohr S; Rao AV; Walker AR; Blachly JS; Piccioni F; Armstrong SA; Byrd JC; Oellerich T; Stegmaier K
Cancer Discov; 2020 Feb; 10(2):214-231. PubMed ID: 31771968
[TBL] [Abstract][Full Text] [Related]
20. Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells.
Mizuno K; Tagawa Y; Mitomo K; Arimura Y; Hatano N; Katagiri T; Ogimoto M; Yakura H
J Immunol; 2000 Aug; 165(3):1344-51. PubMed ID: 10903736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
